Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ALBERTDAVD.NS
Strong BuyFull HouseAlbert David Limited · Healthcare · India · $51M · Avg Vol: $171K/d
93
StockRankGet insider-trade alerts
Q
54
V
56
M
85
P/E (TTM)
21.5x
ROE
-0.4%
D/E
0.1x
Dividend %
0.6%
COMPANY DESCRIPTION
Albert David Limited manufactures and trades in pharmaceutical formulations, infusion solutions, herbal dosage forms, and bulk drugs in India and internationally. It offers formulations for parenterals, oral/enterals, topical agents, aerosol, and vision care products.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 3.4B | 3.6B | 3.4B | 3.3B | -1.1% | 3.6B |
| EPS (INR) | 63.39 | 132.15 | 30.14 | -2.62 | -31.0% | 39.50 |
| Shares | 5.7M | 5.7M | 5.7M | 5.7M | 0.0% | 5.7M |
| Debt | 53.2M | 33.2M | 123.2M | 295.8M | 77.2% | 295.8M |
| Equity | 3.1B | 3.8B | 3.9B | 3.9B | 7.9% | — |
| Op CF | 105.2M | 455.0M | -284.4M | -76.6M | 332.7% | -76.6M |
| Inv CF | -50.0M | -332.5M | 233.0M | -44.0M | — | — |
| Fin CF | -63.6M | -82.7M | 1.1M | 119.2M | — | — |
Loading 1Y...
PRICE (1Y)+24.4%
SMA 50SMA 200
Close
$8.94
RSI (14)
53.4
52W High
$9.80
From 52W High
0.9%
SCORE BREAKDOWN
Quality
54
ROIC
7.5%63.1
ROE
-0.4%44.0
GP/Assets
46.2%83.5
Op. Margin
8.2%58.9
FCF/Assets
-7.1%32.6
Piotroski
25.9
Int. Cover
11.7x64.1
D/E Ratio
0.08x66.2
Current Ratio
3.24x58.2
Value
56
P/E (TTM)
21.5x56.9
EV/EBITDA
9.4x72.5
P/FCF
—N/A
P/B
1.2x79.9
P/S
1.3x78.2
Div Yield
0.6%18.1
Momentum
85
52W High %
91%86.8
RS 6M
36%87.3
SMA 50/200
1.05x68.1
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
303%94.8
FUNDAMENTALS
Market Cap
$51M
P/E (Forward)
—
Gross Margin
65.8%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ALBERTDAVD.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ALBERTDAVD.NS | Albert David Limited(you) | $51M | 93 | Strong Buy |
| AHCL.NS | Anlon Healthcare Limited | $88M | 90 | Strong Buy |
| VALIANTLAB.NS | Valiant Laboratories Limited | $65M | 83 | Strong Buy |
| ANUHPHR.NS | Anuh Pharma Limited | $101M | 94 | Strong Buy |
| AMANTA.NS | Amanta Healthcare Limited | $83M | 81 | Strong Buy |
| JAGSNPHARM.NS | Jagsonpal Pharmaceuticals Limited | $165M | 94 | Strong Buy |
| LINCOLN.NS | Lincoln Pharmaceuticals Limited | $135M | 99 | Strong Buy |
| SYNCOMF.NS | Syncom Formulations (India) Limited | $208M | 96 | Strong Buy |
| ZIMLAB.NS | ZIM Laboratories Limited | $73M | 67 | Buy |
| WANBURY.NS | Wanbury Limited | $91M | 69 | Buy |
Peer medians: ROE 11.9% · P/E 42.8x · Gross margin 59.4%